Case study: impact of technology investment on lead discovery at Bristol-Myers Squibb, 1998-2006

Drug Discovery Today

Volumn 13, Issue 1-2, 2008, Pages 44-51

  Houston, John G ^a   Banks, Martyn N ^a   Binnie, Alastair ^a   Brenner, Stephen ^a   O'Connell, Jonathan ^a   Petrillo, Edward W ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOMATION; BIOASSAY; COMPUTER ANALYSIS; DRUG INDUSTRY; DRUG RESEARCH; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH THROUGHPUT SCREENING; REVIEW; STORAGE; STRUCTURE ACTIVITY RELATION; TECHNOLOGY;

CAPITAL EXPENDITURES; DRUG DESIGN; DRUG INDUSTRY; INVESTMENTS; PRIVATE SECTOR; TECHNOLOGY, PHARMACEUTICAL;

EID: 37749002867     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2007.11.004     Document Type: Review

References (47)

1. Houston J.G., and Banks M.N. The chemical-biological interface: developments in automated and miniaturized screening technology. Curr. Opin. Biotechnol. 8 (1997) 734-740
2. st century. Curr. Opin. Chem. Biol. 4 (2000) 445-451
3. Karet G. Transforming HTS. Drug Discov. Dev. 5 (2002) 20-27
4. Lane S.J., et al. Defining and maintaining a high quality screening collection: the GSK experience. Drug Discov. Today 11 (2006) 267-272
5. Archer J.R. History, evolution, and trends in compound management for high throughput screening. ASSAY Drug Dev. Technol. 2 (2004) 675-681
6. Wood T., and Keghley W. Automation sample supply for high throughput screening. Eur. Pharm. Rev. 9 (2004) 68-73
7. Wallace R.W., and Goldman M.E. Bioassay design and implementation. In: Devlin J.P. (Ed). High Throughput Screening: The Discovery of Bioactive Substances (1997), Marcel Dekker, New York 279-305
8. Banks M.N., et al. High-throughput screening: evolution of technology and methods. In: Shayne Cox G. (Ed). Drug Discovery Handbook (2005), John Wiley & Sons, Inc. 559-602
9. Janzen W.P. Lab Robot. Automat. 8 (1996) 261-265
10. th edn Vol. 2 (2003), Drug Discovery and Development 37-69
11. Bojanic D., et al. Factors for the successful integration of assays, equipment, robotics, and software. In: Devlin J.P. (Ed). High Throughput Screening: The Discovery of Bioactive Substances (1997), Marcel Dekker, New York 493-508
12. Imming P., et al. Opinion: drugs, their targets and the nature and number of drug targets. Nat. Rev. Drug Discov. 5 (2006) 821-834
13. Zambrowicz B.P., and Sands A.T. Knockouts model the 100 best selling drugs-will they model the next 100?. Nat. Rev. Drug Discov. 2 (2003) 38-51
14. Lindsay M.A. Target discovery. Nat. Rev. Drug Discov. 2 (2003) 831-838
15. Nuttall M.E. Drug discovery and target validation. Cells Tissues Organs 169 (2001) 265-271
16. McGee P. Lean practices beef up pipeline. Drug Discov. Dev. 8 (2005) 26-33
17. Sofia M.J., et al. Compound management: integrating chemistry, biology, and technology in the modern drug discovery environment. Pharmaceut. Discov. 5 (2005) 22-31
18. Pearce B.C., et al. An empirical process for the design of high-throughput screening deck filters. J. Chem. Inf. Model. 46 (2006) 1060-1068
19. Padmanabha, et al. HTS quality control and data analysis: a process to maximize information from a high-throughput screen. Combinat. Chem. High Throughput Screen. 8 (2005) 521-527
20. Johnson S.R., et al. A simple strategy for mitigating the effect of data variability on the identification of active chemotypes from high-throughput screening data. J. Biomol. Screen. 12 (2007) 276-281
21. Ellson R., et al. Transfer of low nanoliter volumes between microplates using focused acoustics - automation considerations. J. Assoc. Lab. Automat. 8 (2003) 29-34
22. Sittampalam G., et al. HTS: advances in assay technologies. Curr. Opin. Chem. Biol. 11 (1997) 1384-1391
23. Kolb A.J., et al. Homogeneous, time-resolved fluorescence method for drug discovery. In: Devlin J.P. (Ed). High Throughput Screening: The Discovery of Bioactive Substances (1997), Marcel Dekker, New York 345-376
24. Cook N.D. Scintillation proximity assay, a versatile high throughput screening technology. Drug Discov. Today 1 (1996) 287-294
25. Larry C., et al. Seeing the light: calcium imaging in cells for drug discovery. Drug Discov. Today 5 Suppl. 1 (2000) 15-19 1
26. Cuatrecasas P. Drug discovery in jeopardy. J. Clin. Invest. 116 (2006) 2837
27. Frantz S. Nat. Rev. Drug Discov. 6 (2007) p7
28. Landers, P. (2004) Human element: drug industry's big push into technology falls short. Wall Street J. February 2005 issue, 1
29. Mullin R. As high throughput screening draws fire, researchers leverage science to put automation into perspective. Chem. Eng. News 82 (2004) 23-32
30. Das J., et al. 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2- methyl-4pyrimidinyl] amino)]-1,3-thiazole-5-carboxamide (Dasatanib, BMS-354825) as a potent pan-Src kinase inhibitor. J. Med. Chem. 49 (2006) 6819-6832
31. Chen T., et al. High throughput screening identified a substituted imidazole as a novel RANK pathway-selective osteoclastogenesis inhibitor. ASSAY Drug Dev. Technol. 4 (2006) 387-396
32. Tarby C.M., et al. Inhibitors of human mitotic kinesin Eg5: characterization of the 4-phenyl-tertahydroisoquinoline lead series. Bioorg. Med. Chem. Lett. 16 (2006) 2095-2100
33. Ellsworth B.A., et al. Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series. Bioorg. Med. Chem. Lett. 17 (2007) 3978-3982
34. Williams G.P. Advances in high-throughput screening. Drug Discov. Today 9 (2004) 515-516
35. Fox S., et al. High Throughput screening 2002: moving towards increased success rates. J. Biomol. Screen. 7 (2002) 313-316
36. Macarron R. Critical review of the role of HTS in drug discovery. Drug Discov. Today 11 (2006) 277-279
37. Schmidt E.F., and Smith D.A. R&D technology investments: misguided and expensive or a better way to discover medicines?. Drug Discov. Today 11 (2006) 775-784
38. Fox S., et al. High-throughput screening: update on practices and success. J. Biomol. Screen. 11 (2006) 864-869
39. Keseru G.M., and Makara M.M. Hit discovery and hit-to-lead approaches. Drug Discov. Today 11 (2006) 15-16
40. Wilhelm S., et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5 (2006) 835-844
41. Bleicher K.H., et al. Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discov. 2 (2003) 369-378
42. Carroll J. Better drug discovery through better target identification. Biotechnol. Healthcare February (2005) 52-58
43. Houston J.G., et al. Technologies for improving lead optimization. Am. Drug Discov. 1 (2006) 6-15
44. Cacace A., et al. An ultra-HTS process for the identification of small molecule modulators of orphan G-protein-coupled receptors. Drug Discov. Today 8 (2003) 785-792
45. ®. J. Biomol. Screen. 11 (2006) 854-863
46. ® technology. J. Biol. Chem. 280 (2005) 11704-11712
47. Silen J.L., et al. Screening for novel antimicrobials from encoded combinatorial libraries by using a two-dimensional agar format. Antimicrob. Agents Chemother. 42 (1998) 1447-1453